Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of JNJ-32729463 versus moxifloxacin in hospitalized community-acquired bacterial pneumonia
2010-021574-11Phase 2Completed
- Sponsor
- Furiex Pharmaceuticals
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in community acquired pneumonia (CAP) comparing JNJ-32729463 with Avelox (2 arms). Primary endpoint: Clinical outcome at test-of-cure. Started Oct 2010; status: completed.
02
Drugs
acorafloxacinmoxifloxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2010-021574-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021574-11.